Hr Positive Her2 Negative Advanced Breast Cancer clinical trials

Explore recruiting hr positive her2 negative advanced breast cancer clinical trials.

Recruiting hr positive her2 negative advanced breast cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Hr Positive Her2 Negative Advanced Breast Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

EPIK-B5: A Phase III, randomized, double-blind, placebo-controlled study of alpelisib (BYL719) in combination with fulvestrant for men and postmenopausal women with HR-positive, HER2-negative advanced breast cancer with a PIK3CA mutation, who progressed on or after aromatase inhibitor and a CDK4/6 inhibitor

Slovakia, Ireland, Bulgaria, Romania, Poland, Greece +10 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

BYLieve: A phase II, multicenter, open-label, three-cohort, non-comparative study to assess the efficacy and safety of alpelisib plus fulvestrant or letrozole in patients withPIK3CA mutant, hormone receptor (HR) positive, HER2-negative advanced breast cancer (aBC), who have progressed on or after prior treatments.

Denmark, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1)

Poland, Czechia, Romania, Austria, Belgium, France +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Hr Positive Her2 Negative Advanced Breast Cancer trials by city

Hr Positive Her2 Negative Advanced Breast Cancer in Toronto Hr Positive Her2 Negative Advanced Breast Cancer in Vancouver Hr Positive Her2 Negative Advanced Breast Cancer in Montreal Hr Positive Her2 Negative Advanced Breast Cancer in Calgary Hr Positive Her2 Negative Advanced Breast Cancer in Edmonton Hr Positive Her2 Negative Advanced Breast Cancer in Ottawa Hr Positive Her2 Negative Advanced Breast Cancer in Winnipeg Hr Positive Her2 Negative Advanced Breast Cancer in Quebec City Hr Positive Her2 Negative Advanced Breast Cancer in Hamilton Hr Positive Her2 Negative Advanced Breast Cancer in Kitchener Hr Positive Her2 Negative Advanced Breast Cancer in London Hr Positive Her2 Negative Advanced Breast Cancer in Halifax Hr Positive Her2 Negative Advanced Breast Cancer in New York Hr Positive Her2 Negative Advanced Breast Cancer in Los Angeles Hr Positive Her2 Negative Advanced Breast Cancer in Chicago Hr Positive Her2 Negative Advanced Breast Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease